Inatural Biotech

iNatural Biotech is a clinical-stage biotechnology company based in Taiwan that specializes in the discovery and development of botanical drugs. The company utilizes its proprietary iNatural AI platform, which combines a massive natural product database with advanced computational screening to identify therapeutic candidates from traditional medicinal sources. Its lead program, INB-01, is a botanical drug candidate currently in Phase 2 clinical trials for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Beyond ADHD, iNatural Biotech is advancing a pipeline of candidates for neurodegenerative diseases, including Alzheimer's disease, and metabolic disorders. The company's mission is to transform traditional natural medicine into scientifically validated, globally recognized pharmaceuticals.